Six cell-based new drugs undergoing clinical trials in the United States and Taiwan:

 - Chondrochymal: For knee osteoarthritis, in Phase 2 with primary completion in 2024.
 - Biochymal: For unhealed wounds, in Phase 2 with primary completion in 2024.
 - TWB-201: Precision cell bank for acute myocardial infarction, in Phase 1.
 - MSC-VEGF: SuperCarrier MSC for critical limb ischemia, in Preclinical.
 - TWB-311 & TWB-321: Genetically engineered MSC for SLE and autoimmune diseases, in Preclinical.

We have Co-Developed Exosome Products with Taibao BIO.

Currently Used for Knee Injuries, Eye Diseases, Post-COVID Conditions, Hair Growth Treatments, Skin Beauty Treatments.